Abstract #0928

MRS based biomarkers of IDH1 mutant glioma response to the BAY-1436032 IDH inhibitor

Donghyun Hong¹, Georgios Batsios¹, Pavithra Viswanath¹, Anne Marie Gillespie¹, Russell O Pieper^2,3, Joseph Costello², and Sabrina M Ronen ^1,3

¹Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, ²Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States, ³Brain Tumor Research Center, University of California San Francisco, San Francisco, CA, United States

Mutant IDH1 inhibitor treatment is currently in clinical trials for glioma patients. However, to date, treatment does not result in tumor shrinkage. Therefore, in vivo biomarkers are needed to assess early therapeutic response. Here we treated mutant IDH1-expressing cells with the emerging inhibitor BAY-1436032. Using ¹H MRS we found a significant decrease in 2-hydroxyglutarate that was accompanied by an increase in glutamate and phosphocholine, and using ¹³C MRS we detected a significant increase in glutamate produced from hyperpolarized [1-¹³C]α-ketoglutarate.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.